MEI TANG, MD
Medical Oncology Physician · BALTIMORE, MD
Individual Active NPI 1457495483
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 990 | 537,491 | $31,234,402 | $15,248,579 | $12,133,552 |
| 2023 | 986 | 570,841 | $28,196,891 | $13,934,916 | $11,081,941 |
| 2022 | 1,056 | 574,274 | $26,417,625 | $13,325,323 | $10,610,747 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 76,400 | $51 | $41 |
| J1453 | Injection, fosaprepitant, 1 mg | 39,300 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 34,200 | $49 | $39 |
| J9299 | Injection, nivolumab, 1 mg | 33,170 | $25 | $20 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 31,426 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 28,518 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 21,000 | $26 | $21 |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 9,790 | $48 | $39 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 7,166 | $0 | $0 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 6,630 | $26 | $20 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 6,220 | $7 | $6 |
| J9171 | Injection, docetaxel, 1 mg | 6,180 | $1 | $1 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | D069329 | MD |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Maryland
- NPI 1427497551
- NPI 1124511092
- NPI 1114976065
- NPI 1164089843
- NPI 1780738229
- NPI 1184642548
- NPI 1770546830
- NPI 1063450989
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.